OmniAb Inc OABI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $2.24
- Day Range
- $2.35–3.12
- 52-Week Range
- $1.30–3.12
- Bid/Ask
- $3.06 / $3.07
- Shares Outstanding
- 144.97M
- Market Cap
- $446.52M
- Volume/Avg
- 3M / 716,837
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 10.01
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners’ drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 89
- Website
- https://www.omniab.com
Valuation
|
Metric
|
OABI
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.72 |
Price/Sales | 10.01 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
OABI
|
|---|---|
Quick Ratio | 4.53 |
Current Ratio | 4.80 |
Interest Coverage | — |
Quick Ratio
OABI
Profitability
|
Metric
|
OABI
|
|---|---|
Return on Assets (Normalized) | −10.28% |
Return on Equity (Normalized) | −11.53% |
Return on Invested Capital (Normalized) | −11.59% |
Return on Assets
OABI
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|R@??&?% | LOCK|^NJG | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|%SG<&? | LOCK|RC@@ | $79B | |||
| argenx SE ADR
ARGX
| LOCK|<^p?^z | LOCK|#> | $54B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|m!%&s#l | LOCK|tnt> | $50B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|G%^!##p | LOCK|?SQ | $39B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|YFjkM< | LOCK|?^!$ | $31B | |||
| Incyte Corp
INCY
| LOCK|VmM>!fw | LOCK|<> | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|>HyMxv | LOCK|CL | $23B | |||
| Moderna Inc
MRNA
| LOCK|KQF<%yq | LOCK|J! | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|d!nVNtP | LOCK|BQv | $17B |
United States